NEW YORK – Enzo Biochem reported after the close of the market on Tuesday that its fiscal fourth quarter revenues fell 8 percent year over year, reflecting new, "sharply lower" industry-wide reimbursement rates under the Protecting Access to Medicare Act (PAMA).
For the three months ended July 31, the diagnostics company said total revenues sank to $20.9 million from $22.8 million a year earlier.